Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 66 | 69 | +3 |
| Shares | 41.2M | 39.8M | −1.46M (−3.6%) |
| Value | $313.8M | $309.8M | −$3.96M (−1.3%) |
New holders (10)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baker Bros. Advisors LP | 375,095 | $2.92M | 0.02% |
| ExodusPoint Capital Management, LP | 261,593 | $2.04M | 0.02% |
| UBS Oconnor LLC | 95,528 | $744.2K | 0.02% |
| Dimensional Fund Advisors LP | 37,268 | $290.3K | 0.00% |
| Silverarc Capital Management, LLC | 31,156 | $242.7K | 0.11% |
| Squarepoint Ops LLC | 13,998 | $109.0K | 0.00% |
| Susquehanna International Group, LLP | 13,111 | $102.1K | 0.00% |
| Jane Street Group, LLC | 12,349 | $96.2K | 0.00% |
| Two Sigma Investments, LP | 10,100 | $78.7K | 0.00% |
| Wells Fargo & Company | 5,517 | $43.0K | 0.00% |
Sold out (7)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| RTW Investments, LP | 1,214,572 | $9.24M |
| Woodline Partners LP | 511,351 | $3.89M |
| OrbiMed Advisors LLC | 27,369 | $208.3K |
| Cubist Systematic Strategies, LLC | 24,619 | $187.4K |
| DekaBank Deutsche Girozentrale | 16,500 | $121.0K |
| Virtus Investment Advisers, Inc. | 12,638 | $96.2K |
| CWM, LLC | 34 | $0 |